INTRODUCTION
The canine lysosomal acidic ß-galactosidase (GLB1, EC 3.2.1.23) is an exoglycosidase that removes ß-ketosidically linked galactose residues from glycoproteins, sphingolipids and keratan sulphate (VAN DER SPOEL et al. 2000) . GM 1 -gangliosidosis is an autosomal recessively inherited lysosomal storage disease caused predominantly by structural defects in the ß-galactosidase gene (GLB1) (THOMAS et al. 1995) . The GLB1 gene is located on chromosome 3p21 in humans and on chromosome 23 in dog (PRIAT et al. 1998; BREEN et al. 2001) . Both orthologous GLB1 genes contain 16 exons and share 86.5% identity at the nucleotide level and 81% identity at the amino acid level (WANG et al. 2000) . In both species GLB1 is synthesized as a 85 kDa precursor protein, which is subsequently processed into a 64-66 kDa mature form and a 22-24 kDa cleavage fragment (CALLAHAN, 1999) . Comparative studies carried out on human, mouse and bovine GLB1 revealed that the released 22-24 kDa proteolytic fragment remains associated to the 64-66 kDa chain to form the catalytically active ß-galactosidase (D' AZZO et al. 1982; BOUSTANY et al. 1993) . The significance of the 22-24 kDa C-terminal GLB1 domain, encoded partially by exon 15 and 16, is supported by the identification of several amino acids substitutions in different forms of GM 1 -gangliosidosis in canine and human patients (BOUSTANY et al., 1993 ; VAN DER SPOEL et al., 2000; MORRONE et al. 2000; WANG et al. 2000; YAMATO et al. 2002) .
Many disease-associated mutations affect pre-mRNA splicing, usually causing incorrect exon assembly (CRATEGNI et al. 2002) . Up to 15% of point mutations responsible for genetic diseases in humans cause aberrant splicing (KRAWCZAK et al. 1992) . The most common consequence of these mutations is exon skipping. In constitutive splicing all exons are included in the mature mRNA, whereas in the skipped pattern one or more exons are missing.
The regulation of this process is still not very well understood; so far, cis-regulatory elements such as exonic splicing enhancers (ESEs) were mostly identified in individual cases (SCHAAL 5 and MANIATIS, 1999; FAUSTINO et al. 2003; BLACK, 2003) . Analysis of candidate sequences demonstrated that purine rich motifs (GGAGA/GGGA/AGAGA) and CA-rich consensus motifs (C)CACC(C) are frequently used as splicing enhancer elements (DU et al. 1997; LIU et al. 1998; ROMANO et al. 2002; MIRIAMI et al. 2003; FAIRBROTHER et al. 2004) .
In a previous study we reported clinical and pathological findings in Alaskan Huskies with GM 1 -gangliosidosis (MÜLLER et al. 1988; MÜLLER et al. 2001) . The objective of the present study was to identify the causative genetic defect. Therefore, the GLB1 gene and the GLB1 mRNA processing were investigated in a family of Alaskan Huskies with GM 1 -gangliosidosis.
MATERIALS AND METHODS

Animals:
A large pedigree of Alaskan Huskies segregating for GM 1 -gangliosidosis was available (MÜLLER et al. 2001) . Affected and related heterozygous carrier animals previously classified by clinical, biochemical and pathological investigations were used for nucleic acids isolation (Figure 1 ). RNA from DH82 cells (ATCC CRL-10389) and canine primary skin fibroblasts from two healthy control dogs (Airedale Terrier C 1 and Dachshund C 2 ) was used as controls in RT-PCR experiments.
DNA analysis: Genomic DNA was isolated from canine skin fibroblast cell cultures using the Puregene® kit (Biozym, Germany). All enzymatic reactions were carried out in a DNA Programmable Thermal Controller (PTC-200; MJ Research, Cambridge, MA, USA). PCR reactions were performed using primers Ex15_F and Ex15_R (Table 1) , and the KOD Hot Start DNA Polymerase (Novagen, Darmstadt, Germany). The PCR amplifies a 182 bp product within exon 15 of the GLB1 gene (Table 1 ). The resulting PCR-products were cloned and sequenced to confirm their identity. The sequencing reactions were performed by MWG Biotech (Ebersberg, Germany).
RNA analysis: Mutation analysis of the whole coding region of the canine GLB1 cDNA was performed on total RNA isolated from canine skin fibroblasts using TRIzol™ Reagent (Invitrogen, Carlsbad, CA, USA). The SMART-RACE™ method (Clontech, Palo Alto, CA, USA) was used for cDNA synthesis. For the first strand cDNA synthesis 100 ng total RNA and the SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) were used. The second strand synthesis was performed using 10 µl first strand cDNA and the Advantage™ GC PCR Polymerase Mix (Clontech, Palo Alto, CA, USA). The obtained double stranded cDNA was purified with the QIAquick® PCR purification kit (Qiagen, Hilden, Germany). In subsequent 25 µl-PCR reactions 100 ng double stranded cDNA, primers Ex1_F and Ex16_R (Table 1 ) and the KOD Hot Start polymerase were used. The resulting RT-PCR-products were cloned and sequenced (2 independent clones each) or directly sequenced.
Sequence analysis and bioinformatics: Sequences were assembled and analyzed for mutations with Sequencher 4.2 (Genecodes, Ann Arbor, MI). In order to predict the possible localization of SR-protein-specific putative exonic sequence enhancers (ESEs), a web-based tool, the ESEfinder Release 2.0 was used (http://rulai.cshl.edu/tools/ESE/). The default threshold values were set as the median of the highest score for each sequence in a set of 30 randomly chosen 20 nucleotides sequences previously used for functional SELEX (CRATEGNI et al. 2003) .
RESULTS
At the beginning of the study a large pedigree of Alaskan Huskies segregating for GM 1 -gangliosidosis was available (Figure 1 A) . We had previously measured the biochemical activity of GLB1 in these dogs, which confirmed that the affected dogs had very little GLB1 activity (MÜLLER et al. 1998; MÜLLER et al. 2001) . Therefore, we started to investigate whether mutations in the GLB1 gene are causative for this defect. We amplified full-length cDNAs from dogs with the three different postulated genotypes (homozygous mutated, heterozygous, and homozygous wildtype). Surprisingly, when the RT-PCR products were separated on agarose gels, a homozygous mutated and a heterozygous animal apparently showed the same pattern of two different bands, while only the homozygous wildtype animal showed a single band of the expected size (Figure 1 B) . Sequencing of these RT-PCR products revealed that the smaller band seen in the affected and heterozygous dogs corresponded to a transcript, in which exon 15 was missing. Sequencing of the larger RT-PCR product in the affected dog showed that this band corresponded to a full-length GLB1 transcript, however it contained a 19 bp duplication in the region encoded by exon 15. This duplication was additionally confirmed by direct RT-PCR and PCR analyses of exon 15 (Figure 1 C, D) . The duplication corresponded to positions +1688 -+1706 in the canine GLB1 8 cDNA and had the sequence 5'-TCCCAGACTTGCCCCAGGA-3' (Figure 1 E) . In order to ensure that the observed mutation is indeed the causative pathological mutation, a sample of 30 normal dogs of different breeds was tested for the presence of the 19 bp duplication. The duplication was not present on any of the 60 chromosomes studied.
Our results indicate that the 19 bp duplication in exon 15 leads to exon skipping in a portion of the GLB1 transcripts and two different mRNA species are expressed from the mutant allele (Figure 2) . The results of the affected dog were confirmed in the heterozygous dog, where actually the presence of three different mRNA species was established after DNA sequencing.
In addition to the normal GLB1 mRNA from the wildtype allele, heterozygous dogs also express mRNAs lacking exon 15 and full-length mRNAs with the 19 bp duplication. In the other aberrant transcript variant, which contains exon 15 with the duplication, the insertion of 19 additional nucleotides leads to a frame-shift and the apparition of a premature termination codon (PTC). As the PTC resides in the last exon, the transcript is not subject to nonsense-mediated decay (NMD). The band intensities of the gels with the RT-PCR products suggest that it is present in comparable amounts as the transcript lacking exon 15. This transcript containing exon 15 with the 19 bp duplication gives rise to a protein that is 78 amino acids shorter than the wildtype GLB1 and additionally has a completely different C-terminal sequence. Both transcripts from the mutated allele are thus likely to encode completely non-functional GLB1 proteins 9
DISCUSSION
In the present study a novel 19 bp duplication in exon 15 of the canine GLB1 gene was identified as causative mutation for GM 1 -gangliosidosis in Alaskan Huskies. The mutation corresponded to nucleotides +1688 -+1706 of the GLB1 cDNA. The GLB1 mutation causing GM 1 -gangliosidosis in Alaskan Huskies is thus different from earlier described GLB1 mutations in Portugese Waterdogs and Shiba Inus (WANG et al. 2000; YAMATO et al. 2002) The Potugese Waterdog mutation is a point mutation (R60H) whereas the Shiba Inu mutation represents a 1 bp deletion leading to a frame-shift and PTC.
The newly identified GLB1 mutation causes very peculiar aberrations in RNA processing. In animals carrying the 19 bp duplication normal and abnormal splicing of GLB1 pre-mRNA coexists. The 19 bp duplication interferes with the recognition of exon 15 leading to exon skipping of this exon in a fraction of all transcripts, while the remaining transcripts are normally spliced. Exon recognition is becoming more and more accepted as an important mechanism in the splicing of mammalian transcripts (BERGET, 1995) . The mechanism by which exons are recognized or defined is not completely understood. So far, it seems clear that there is an interaction between splicing factors across exons and that these interactions are often mediated by auxiliary proteins such as SR-proteins that bind to the exon sequence itself (BERGET, 1995; BIANCA AND HERTEL, 2002) . The in silico analysis of potential binding sites for SR-proteins in exon 15 of the canine GLB1 gene revealed that the 19 bp duplication leads to the presence of potential additional binding sites for SF2/ASF, SC35, and SRp40, respectively. Thus, it seems conceivable that the precise binding of one or more of these proteins is essential for the correct exon recognition of exon 15. This implies a hypothetical explanation for the peculiar observation that two different mRNAs are produced from the mutant allele: In pre-mRNAs with the 19 bp duplication a splicing factor might bind to one of two alternative binding sites. However, only one of the two alternative binding sites is in the correct distance to the 3'-end of exon 15 and only binding to this site leads to inclusion of exon 15 in the mature transcript. If the binding site with the wrong distance to the 3'-end of exon 15 is occupied this would lead to exon skipping. As the sequences in the two duplicated 19 bp segments are identical the chance that a potential binding protein binds to the correct binding site is 50%, which corresponds to the experimental observation that the amounts of the two transcripts are roughly equal in fibroblasts.
In conclusion, we describe a novel 19 bp mutation in the canine GLB1 gene that causes interesting aberrations of the normal splicing process. The molecular elucidation of the GM 1 -gangliosidosis in Alaskan Huskies provides another model for the human GM 1 -gangliosidosis. Knowledge of the causative mutation for GM 1 -gangliosidosis in Alaskan Huskies will also allow genetic testing of these dogs to avoid accidental matings of carrier animals. Thus breeders will be enabled to eliminate this disease from their breeding lines. 
TABLES
